Stroboscopic Vision Training in Softball

June 24, 2026 updated by: Texas Tech University Health Sciences Center

Effect of Stroboscopic Vision Training in a Softball Season: A Randomized Controlled Trial Pilot Study

Enhanced sports performance, in our current world, is being pushed at the professional level and down to school-age children as well. Money is being spent on lessons and equipment to enhance performance. One new method to enhance performance is stroboscopic vision goggles. The glasses lenses flicker removing visual information for a brief moment. The claim is that they train connections between the eyes, brain, and body. We want to see if this product truly does enhance visual performance during a softball season for high school girls.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

In today's sports world, every strategy to perform at the highest level is needed. Current literature is demonstrating enhanced sports performance using stroboscopic vision training.1,2,5 The objective of this randomized controlled trial is to measure the effect of a stroboscopic visual training in a high school softball season in comparison to controls. Athletes in the control group will go through normal practice drills for hitting and fielding. The stroboscopic training (experimental group) will use the strobe glasses during hitting and fielding drills two times a week in practice. The brand of strobe glasses is Senaptec Strobe. Athletes in both the experimental and control groups will have their vision assessed at the beginning of the season and end by The West Texas Vision Center. Measurements for vision will include developmental eye movement, vergence ranges, Randot stereopsis test, accommodative ranges, acuity, and stereo scores. On-field performance measurements will be collected for batting statistics including on-base percentage, batting average, slugging percentage, and hard-hit ball percentage in both the experimental and control groups. The current year batting statistics will be compared with the prior year statistics if enough at-bats occurred. In addition, to the vision and on-field hitting performance proprioception balance using the Balance Error Scoring System (BESS) will be measured at the beginning of the season and end for both groups. Our data will provide quantified information for coaches, athletes, and health care providers concerning the benefits of the strobe glasses warrant buying to enhance sports performance. Additionally, we wish to determine whether visual-motor and proprioception balance changes occur after the training.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
34

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Lubbock, Texas, United States, 79430
        • Texas Tech University Health Sciences Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 1) Age 14-18 years 2) females; 3) high school softball

Exclusion Criteria:

  • 1) Prior use of stroboscopic vision training; 2) History of seizures; 3) History of vestibular impairments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Stroboscopic Training Group
Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
Device: Senaptec Strobe Glasses
The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
Active Comparator: Standard softball drills
Control group, which will perform normal hitting and fielding drills without stroboscopic training
Other: Standard softball drills
Control group, which will perform normal hitting and fielding drills without stroboscopic training

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Vergence ranges
Time Frame: 8 weeks
Vergence ranges measured how many prism diopters the subject can turn their eyes in (base out) and how far they can relax them out (base in). This score is also a good measure of how much peripheral fusion a person has.
8 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Developmental eye movement
Time Frame: 8 weeks
Developmental eye movement will measure how fast the subject can track numbers vertically and horizontally.
8 weeks
Randot stereopsis test
Time Frame: 8 weeks
Randot stereopsis test will measures how many ARC seconds of stereo the subject has. This test measures the subject's magno and parvocellular stereo tracking their peripheral or central fusion.
8 weeks
Accommodative ranges
Time Frame: 8 weeks
Accommodative ranges will measure how many times the subject can clear an image looking through a plus and minus accommodation flipper in thirty seconds.
8 weeks
Acuity
Time Frame: 8 weeks
Acuity will measure the clarity of vision at a distance of twenty feet.
8 weeks
Stereo Scores
Time Frame: 8 weeks
Stereo Scores will measure how quickly the athlete recognizes depth perception
8 weeks
Batting statistics
Time Frame: 8 weeks
Batting statistics including on-base percentage, batting average, slugging percentage, hard-hit ball percentage will be provided by the coach at the end of the season for the current year and prior year. Subjects will need a minimum of 20 at-bats in a season for collection of these statistics.
8 weeks
Balance Error Scoring System (BESS)
Time Frame: 8 weeks
Balance Error Scoring System (BESS) measures the total number of postural errors committed in a 30-second trial standing on flat surface and foam pad. It provides a measure of balance and proprioceptive ability.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Texas Tech University Health Sciences Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 29, 2021

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 29, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 12, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 16, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • L20-095

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings